Researchers launched a unique collaboration on Wednesday aimed at getting cancer drugs to the market more quickly in which three companies will cooperate with the U.S. government and non-profit groups to test five experimental breast cancer drugs.
The five-year, $26 million study called Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis, or I-SPY2, will aim to use DNA to match the best drug to each patient and to more quickly toss out approaches that do not work or are too toxic.
"They'll get the latest and greatest in terms of targeted drugs," Dr. Anna Barker, deputy director of the National Cancer Institute, said in an interview.
"I think it's the future. Government couldn't have done it on their own and these companies couldn't have done it on their own."
Unusually, the companies agreed to share information on using genes to predict how well a patient will respond as part of the Biomarkers Consortium, which includes the U.S. Food and Drug Administration and the National Institutes of Health.
"I-SPY 2 will provide a path to personalized medicine," said Dr. Laura Esserman, a breast cancer surgeon at the University of California San Francisco who will help lead the clinical trials. "We intend that every drug will graduate with a companion marker."
The trial will match patients to one of five experimental drugs:
-- ABT-888 or veliparib, being developed by Abbott Laboratories. The pill is a PARP inhibitor, which blocks a cell repair enzyme used by cancer cells.
-- AMG 655 or conatumumab, a targeted drug being developed by Amgen. It boosts a protein called APO/TRAIL that causes cancer cells to self-destruct.
-- Amgen's AMG 386, an angiogenesis inhibitor that stops tumors from growing blood vessels to nourish themselves.
-- CP-751,871 or figitumumab, being developed by Pfizer Inc to target the insulin growth factor receptor or IGFR.
-- Pfizer's HKI-272 or neratinib, another targeted therapy called a Pan ErbB inhibitor that targets several related receptors used by cancer cells.
The group is negotiating with other companies to add their experimental drugs to the mix.
"It'll speed up the whole process," Barker said.
The drug company lobby group PhRMA estimates it can take as long as 15 years and cost more than $1.3 billion dollars to take a new drug from laboratory to pharmacy.
Patients at 20 cancer centers will be tested right after they get tiny samples of tissue taken in biopsies. Before they ever get surgery, they will be treated with one of the drugs to see if this helps prevent tumor spread.
Up to 12 different cancer drugs will be tested. Unusually, the group has FDA approval to drop and add drugs throughout the course of the trial without having to stop it to write a whole new protocol.
No Ebola cases detected for two incubation periods, says World Health Organization
The World Health Organization and leading global health specialists have criticised Saudi Arabia for failing to properly investigate the causes of MERS.
UNICEF predicts that the number of children orphaned by Ebola – which currently stands at nearly 200 – will reach as many as 2,000
UN Article 82 could mean millions in additional costs for drilling companies.
The figures, through Nov. 16, represent a jump of 243 deaths and 732 cases since those issued last Friday, and cases continue to be under-reported, the WHO said in its latest update.
The infectious disease causes total paralysis in a matter of hours. It affects mainly children under five years of age.
The 30-year-old woman was from the province of Minya, south of Cairo. She died in a hospital in the southern city of Assiut
UNAIDS estimated that by June 2014 some 13.6 million people globally had access to antiretroviral medicines - a dramatic improvement on the 5 million who were getting treatment in 2010.
The H5N8 form of the virus has hit a Dutch chicken farm and a German turkey farm and is suspected - but not yet confirmed - as the strain that infected ducks on a British farm.
'Hidden childhood killer' drowning is among the ten leading causes of child and youth deaths, according to WHO's first global report on drowning.
More than 20 species of starfish, also called sea stars, from southern Alaska to Baja California are dying from a wasting disease
Japan has long maintained that most whale species are not endangered and that eating whale is a cherished part of its food culture
The new fatality brings to two the confirmed number of bird flu deaths so far this year
Drug resistance is driven by the misuse and overuse of antibiotics, which encourages bacteria to evolve to survive and develop new ways of beating the drugs.
The country has seen a reduction in the number of new Ebola cases since the beginning of October
MSF, known also as Doctors Without Borders, is the only organisation to have worked extensively with Ebola in the last 20 years